A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
But the new focus on a predictive biomarker could cut the market in half.
On a wing and a prayer Leap heads for phase 3.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company might need something better to replace its ageing blockbuster.
